Key result
STRATIFY models strongly predict 10-year adverse events, achieving a ~0.82 C-statistic for hypotension.
Why the study?
Antihypertensives are linked to increased risk of syncope, hypotension, and fractures, but the highest-risk individuals remain unclear.
Can the STRATIFY models accurately predict the 10-year risk of hypotension, syncope, and fracture in patients aged 40+ indicated for antihypertensive treatment?
Cohort (n=5,578,590)
Yes
Can the STRATIFY models accurately predict the 10-year risk of hypotension, syncope, and fracture in patients aged 40+ indicated for antihypertensive treatment?
Answers are grounded in this paper and cite their sources.
The STRATIFY models provide strong discriminative ability to predict the 10-year risk of hypotension, syncope, and fracture, which can help reassure patients or identify those needing additional monitoring during antihypertensive therapy.
Antihypertensives are associated with increased risk of syncope, hypotension, and fractures, but the highest-risk individuals are unclear. This study aimed to develop and validate three models to predict these outcomes in patients with an indication for antihypertensive treatment. A cohort study was conducted using data from Clinical Practice Research Datalink (CPRD). Patients aged 40+ with systolic blood pressure 130-179 mmHg were included. Outcomes were first hypotension, syncope, or fracture leading to hospitalization or death within 10 years. Models were derived from CPRD GOLD data (n = 1,773,224) and validated with CPRD Aurum data (n = 3,805,366). Each model had 31-37 predictors. Validation demonstrated strong discriminative ability (10-year C-statistic: hypotension 0.824; syncope 0.819; fracture 0.790), with close agreement between predicted and observed risks for the hypotension and syncope models. Some underprediction was observed for the fracture model. These models could be used to help reassure patients about the relatively low risk of harm from antihypertensive treatment, or identify the small number of individuals with a higher risk where additional monitoring may be indicated.
No takes yet. Share an insight, caveat, or question.
Koshiaris et al. (2025) conducted a cohort in Indication for antihypertensive treatment (n=5,578,590). STRATIFY risk prediction models was evaluated on Discriminative ability (C-statistic) for first hypotension leading to hospitalization or death within 10 years (C-statistic 0.824, 95% CI 0.823-0.826). The STRATIFY clinical prediction models demonstrated strong discriminative ability for 10-year risk of adverse events, with C-statistics of 0.824 for hypotension, 0.819 for syncope, and 0.790 for fracture.
Synapse has enriched 10 related papers. Consider them for comparative context: